A Single-center, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Investigate the Relative Efficacy and Safety of Immunotherapy With SUBLIVAC FIX Phleum Pratense (SP) Compared to Placebo in Grass Pollen-Allergic Subjects With IgE-Mediated Seasonal Allergic Rhinoconjunctivitis

Trial Profile

A Single-center, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Investigate the Relative Efficacy and Safety of Immunotherapy With SUBLIVAC FIX Phleum Pratense (SP) Compared to Placebo in Grass Pollen-Allergic Subjects With IgE-Mediated Seasonal Allergic Rhinoconjunctivitis

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Allergic rhinitis; Allergic rhinoconjunctivitis; Grass pollen hypersensitivity
  • Focus Therapeutic Use
  • Sponsors HAL Allergy
  • Most Recent Events

    • 25 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 01 Dec 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 24 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top